Abstract: There is a need for water-based sperm- and egg-friendly vaginal lubricant. We describe novel water-based nature-friendly personal moisturizers and lubricants that relieve vaginal dryness. In addition to being non-spermicidal, sperm- and egg-friendly and biological-fluids mimicking, these personal moisturizers and lubricants also enhance sperm survival and motility, promote binding of sperm to eggs and facilitate the process of fertilization. Novel articles, and systems as well as methods of preparation and use of the novel compositions are also provided.
Type:
Application
Filed:
January 21, 2014
Publication date:
May 29, 2014
Applicant:
AQUATROVE BIOSCIENCES, INC.
Inventors:
Vibha Gupta, Vineet Gupta, Boris Nikolic
Abstract: A migraine treatment formulation is designed to be administered upon onset of migraine symptoms. The migraine treatment formulation is able to reduce the nausea and pain associated with a migraine headache through a pharmaceutical composition that carries a reduced chance of causing digestive discomfort. The treatment formulation accomplishes this through a combination of organic and inorganic agents, administered orally, that are optimized for absorption through the mucosal membrane and the lining of the stomach. The higher absorption rate of the active constituents quickly alleviates the various symptoms associated with a migraine headache while preventing unabsorbed constituents from causing digestive issues.
Abstract: The present invention provides compositions that contain magnesium and threonate, or a threonate precursor molecule, formulated for extended or modified release to provide physiological concentrations over a desired time period. The extended release or modified release form is particularly useful in providing Mg to a subject while avoiding adverse side effects such as diarrhea.
Abstract: As disclosed herein, novel compositions including steroid hormones, such as trimegestone (TMG) and progesterone (P4), provide treatments for term and preterm labor with significant effects on the delay of delivery. Delay and block of delivery occurs when both P4 and TMG are administered late in gestation in pregnant rat and guinea pig animal models. TMG exhibits remarkable drug efficacy, achieving the same inhibition as P4, but at much lower doses. These hereto unknown effects of TMG on the processes of cervical ripening and uterine contraction provide a novel approach for extending pregnancy term, including reducing a likelihood of preterm and/or term labor, along with improved methods of administration. Other diseases and/or conditions may be treated with TMG, such as dysmenorrhea or luteal insufficiency for sustaining pregnancy.
Type:
Application
Filed:
October 27, 2011
Publication date:
May 22, 2014
Applicant:
DIGNITY HEALTH
Inventors:
Robert E. Garfield, Shao-Qing Shi, Leili Shi
Abstract: In one embodiment of the present invention, a pharmaceutically-acceptable single-dosage formulation consists essentially of about 500 mg of vitamin C; about 400 IUs of vitamin D3; about 125 IUs of vitamin E; about 25 mg of vitamin B1; about 3.4 mg of vitamin B2; about 35 mg of niacin; about 35 mg of vitamin B6; about 1.25 mg of folic acid; about 70 mcg of vitamin B12; about 5 mg of pantothenic acid; about 75 mcg of biotin; about 35 mg of magnesium; about 35 mg of zinc; about 1 mg of copper; about 125 mcg of selenium; about 150 mcg of chromium; about 10 mg of alpha lipoic acid; about 35 mg of co-enzyme Q-10; about 400 mcg of lutein; about 125 mcg of lycopene; and at least one or more excipients.
Type:
Grant
Filed:
June 19, 2012
Date of Patent:
May 20, 2014
Assignee:
Vertical Pharmaceuticals, LLC
Inventors:
Steven A. Squashic, Kevin M. Hudy, David C. Purdy
Abstract: Disclosed are formulations for enhancing the in vivo colonization of probiotic microorganisms that include digestive enzymes and probiotic microorganisms, and polysorbate surfactants. The enzymes include lactogenic enzyme formulations that promote growth of Lactobacillus probiotics, bifidogenic enzyme formulations that promote growth of Bifidobacterium probiotics and combination formulations that benefit both types of probiotics. It has been discovered that certain polysorbate surfactants, including polysorbate-60 and polysorbate-80, further promote probiotic microorganism growth, when used with the enzyme formulations. The formulations are preferably compounded as dry powders, to avoid water reaction with the enzymes in blended formulations. Such formulations can be contained in capsules, tablets, packets or bottles and administered orally, either sequentially or in one combined formulation.
Abstract: The present invention relates to methods and compositions for reducing distress dysfunction, including emotional and physical distress. The invention entails co-administration of at least one Receptor Switcher and at least one Endorphin Enhancer. Additionally, at least one Synergistic Enhance and/or at least one Exogenous Opioid are also administered to enhance or prolong the therapeutic effects.
Type:
Application
Filed:
November 5, 2013
Publication date:
May 8, 2014
Applicant:
PONDERA BIOTECHNOLOGIES INC.
Inventors:
Steven Crain, William E. Crain, Stanley M. Crain, Michael Crain
Abstract: Methods of treating chronic post-traumatic encephalopathy (PTE) using regenerative approaches is described. In one embodiment, molecules with capability of stimulating endogenous neural stem cells is provided. In another embodiment, cell therapeutics are provided capable of addressing angiogenic deficits in patients suffering from PTE. In another embodiment, cells are utilized to induce activation of endogenous progenitor cells in the central nervous system of PTE patients. Furthermore, low level laser irradiation is disclosed as a means of treatment of PTE either through direct administration to CNS tissue for stimulation of endogenous progenitor cells and reparative processes, or together with administration of exogenous stem cells, whether autologous or allogeneic. In a further embodiment exogenous stem cells are pretreated with laser prior to administration.
Abstract: The invention disclosed a novel mesoporous silica-based xerogel and its use in hemorrhage control. The mesoporous silica-based xerogel material has tunable mesopores (1-50 nm), high specific surface area (100-1400 m2/g), macroscopical morphology (powder, film, disc, column, etc.) and adjustable compositions (SiO2, CaO and P2O5, etc.) as well as good biodegradation. The mesoporous silica-based xerogels herein effectively promote the blood clotting under various conditions including slow and severe hemorrhage, even at the blood oozing site of bone defect. Meanwhile, the networks of silica-based xerogel with good elastic and mechanic properties, formed by adsorbing a large amount of water, can modulate the cell behavior and tissue growth, and thus promote the wound healing. Additionally, due to the mesoporous structure, the materials have the potential to load drug, thrombin and bioactive factors, which is favorable for the therapeutical efficacy.
Type:
Grant
Filed:
March 13, 2009
Date of Patent:
April 22, 2014
Assignee:
East China University of Science and Technology
Abstract: A system and method for treating hoof related diseases, particularly hairy heel warts (papillomatus digital dermatitis), includes an aqueous solution having a metal astringent at a therapeutically effective concentration. The metal astringent includes aluminum, iron, and mixtures thereof. In preferred embodiments, the metal may include a mixture of monomeric and polymeric species. The polymeric species may be in the form of a polymeric concentrate, such as, for example, polyaluminum chloride or polyferric sulfate. Alternatively, the polymeric species may be formed by partially neutralizing a metal salt. The aqueous solution of the metal astringent is applied to a lower leg and hoof area of an animal using any known application technique, including, but not limited to, foot baths, foams and spray applications. In preferred embodiments, the aqueous solution is applied using an automated dispensing system.
Type:
Grant
Filed:
October 25, 2007
Date of Patent:
April 22, 2014
Assignee:
Ecolab USA Inc
Inventors:
Joseph P. Morelli, Jeffrey R. Fernandes, Edward L. C. Verkaar, Petra Vogt
Abstract: Antimicrobial and algaecidal products are disclosed. In general, the antimicrobial or algaecidal products can be adhered to structural components of buildings and include particles that, when combined with water, produce a solution that is toxic to organisms such as algae. The products provide an algaecidal wash as water percolates on, or through the product, and can prevent or control growth of unsightly algae and other microbes.
Abstract: A pet supplement includes a joint preserving and joint rebuilding composition comprising chicken collagen type II, glucosamine hydrochloride and chondroitin sulfate, a vitamin composition comprising vitamins C, D and K, a mineral composition comprising calcium, magnesium, zinc, copper, manganese and boron, a herbal anti-oxidant cofactor blend comprising citrus bioflavonoids, red grapes anthocyanins, turmeric rhizome, boswellia resin and fennel seed. Each of these ingredients is intimately mixed into the pet supplement and orally delivered to the pet in the form of a segment, paste or powder having a size and weight or other dosage measuring feature adjusted in accordance with the pet's weight. A synergistic action between these ingredients preserves and rebuilds the pet's joints, and is nutritionally beneficial for the pet.
Abstract: The invention discloses the use of a treatment composition for preventing, or reducing, the production of contaminants selected from microorganisms and microorganism-produced toxins by contacting the substrate with the composition. The composition comprises a water glycerol mixture and calcium hydroxide in which the percentage by mass of glycerol in the water glycerol mixture is between 5% and 95%, at least some of the calcium hydroxide is dissolved in the water glycerol mixture and the concentration of the dissolved calcium hydroxide in the water glycerol mixture is at least 1.5 times higher than the maximum concentration of dissolved calcium hydroxide which can be obtained in water alone, thereby preventing or reducing the production of the contaminants. The extent of the prevention or reduction is at least 1.5 times more than the corresponding prevention or reduction produced by a treatment composition comprising water and calcium hydroxide only.
Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
Type:
Application
Filed:
August 8, 2013
Publication date:
April 10, 2014
Applicant:
Sarcode Bioscience Inc.
Inventors:
Thomas Gadek, John Burnier, Min Zhong, Wang Shen, Johan D. Oslob, Kenneth Barr
Abstract: Methods of using a non-irritant, low pH acidic composition to destroy undesirable microorganisms are described. The methods may be used on food products, food processing equipment, and in aqueous solutions.
Abstract: Provided is a method that enables a calcium silicate-based material to be produced more efficiently. The method of producing a calcium silicate-based material comprises: (1) a step of obtaining a reaction product by reacting raw materials containing a calcium component, a silicon component and an aluminum component in an aqueous medium; and (2) a step of forming calcium silicate by subjecting the reaction product to hydrothermal treatment.
Abstract: The disclosure is directed to glass compositions that incorporate copper into an otherwise homogeneous glass and to a method for making such glass. This incorporation of the copper into the glass composition imparts significant antimicrobial activity to the glass. A method of making a copper-containing glass article comprises: batching a glass batch comprising: 40-85 SiO2; 10-40 B2O3; 1-19 Al2O3; 0.1-20 CuO or a selected salt of Cu that is convertible into CuO during melting; 0-20 M2O, wherein M is Li, Na, K, or combinations thereof; 0-25 RO, wherein R is Ca, Sr, Mg, or combinations thereof; and 0-20 ZnO. melting the batch to form a melted glass; and forming the melted glass to form the copper-containing glass article having antimicrobial properties.
Type:
Application
Filed:
March 27, 2012
Publication date:
March 20, 2014
Inventors:
Nicholas Francis Borrelli, Odessa Natalie Petzold, Joseph Francis Schroeder, Thomas Philip Seward, Florence Verrier, Ying Wei
Abstract: The present invention relates to a method for maintaining normoglycemia in a mammal in need thereof, preferably a critically ill patient suffering from acute stress, and to a method for preventing or limiting renal ischemia-reperfusion (I/R) in a mammal, preferably in a critically ill patient suffering from acute stress.
Type:
Application
Filed:
March 6, 2012
Publication date:
March 13, 2014
Inventors:
Hendrik Jan Cornelis Meijerink, Lekhram Changoer
Abstract: The present invention provides novel compositions comprising chitosan and vitamin D or chlorhexidin and vitamin D for the treatment of mucosal and epithelial wounds and for the treatment or prevention of oral, mucosal or dermal infections or inflammations.
Abstract: A novel dietary supplement and methods for manufacturing the said dietary supplement are disclosed for promoting healthy cartilages, connective tissues and bones. The dietary supplement of the present invention comprises glucosamine hydrochloride, collagen, and other dietary ingredients. Some ingredients of the dietary supplement of the present invention help to maintain the functions of cartilages, connective tissues and bones. Some ingredients of the dietary supplement of the present invention also exhibit anti-inflammatory properties. Overall, these ingredients of the dietary supplement are beneficial to the health of human and other animals.
Abstract: Tumor cells exhibit consistent abnormalities in calcium regulation. The present disclosure teaches methods by which such differences are exploited to induce Apoptosis selectively in tumor/cancer cells while sparing normal cells. These methods are based upon employing drugs that, acting in synergistic combinations, trigger selective killing of malignant cells. Since the invention is based upon fundamental cell cycle requirements, to the extent that calcium handling abnormalities are a general characteristic of the malignant state, the methods presented here are widely applicable regardless of tissue of origin and degree of cellular de-differentiation.
Abstract: The invention provides a method of improving one or more clinical outcomes of an individual experiencing an acute respiratory attack. The acute respiratory attack may include acute reversible bronchospasm, severe acute bronchospasm, or acute exacerbation of asthma. The method includes administering to an individual suffering from an acute respiratory attack an effective amount of bedoradrine or a pharmaceutically acceptable salt thereof in combination with a standard of care (SOC) treatment regimen.
Abstract: The invention provides methods for promoting weight loss by an animal, promoting weight loss by an animal while preventing or minimizing loss of lean body mass by the animal preventing a reduction in energy metabolism by an animal reducing the risk of regaining weight by an animal after weight loss, and ameliorating undesirable animal behaviors associated with reduced caloric intake by intermittently feeding an animal a first diet containing calories that meet the animal's maintenance energy requirements and a second diet containing calories that do not meet the animal's maintenance energy requirements. In preferred embodiments, the described feeding pattern and diets are ted in conjunction with one or more weight loss agents.
Abstract: Technologies are described herein for styptic compounds comprising a hemostatic or styptic agent suspended within a hydrophobic carrier medium. Example carrier mediums may include waxes, lipids, oils, or combinations thereof. The compound may be a semisolid at room temperature and soft enough to be easily dispensed and formed into or onto bleeding tissue of an animal or human. The hydrophobic qualities of the carrier medium can protect the styptic agent from absorbing moisture. The carrier medium can mechanically support positioning treatments adjacent to the bleeding tissue. The carrier medium can further serve to mechanically seal the tissue to aid in hemostasis while also protecting the tissue from debris and contamination. The carrier medium can aid in maintaining moisture within the tissue. Slurry-based manufacturing processes can support a substantially homogeneous dispersal of styptic agent throughout the carrier medium.
Abstract: Nutritional compositions for maximizing muscle protein synthesis while minimizing the catabolism of muscle proteins and methods of using same are provided. In this manner, the nutritional compositions may provide for retention of lean body mass, which helps to avoid loss of independence and functionality, as well as to improve quality of life especially in the elderly at risk of sarcopenia and frailty. The nutritional compositions include ?-hydroxyisocaproic acid and citrulline. The composition may include other functional ingredients such as, but not limited to whey protein including whey protein micelles, prebiotic fibers, ?-keto-glutarate, eicosapentaenoic acid, L-carnitine, nucleotides, and amino acids. Methods of administering such nutritional products to individuals in need of same are also provided.
Type:
Application
Filed:
April 18, 2012
Publication date:
February 13, 2014
Applicant:
NESTEC S.A.
Inventors:
Norman Alan Greenberg, Denis Breuille, Zamzam Kabiry (Fariba) Roughead, Doug Bolster, Jennifer Mager
Abstract: The present invention relates to the use of 1-[2-(4-(3-trifluoromethyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one, optionally in the form of its pharmaceutically acceptable acid addition salts and optionally in the form of its hydrates or solvates, for preparing a pharmaceutical composition with a neuroprotective activity.
Abstract: The present invention relates to methods of treating cancer through stasis induction, wherein said stasis-inducing treatment results in reduced blood flow to the cells of said cancer, leading to diminished tumor growth and/or tumor death. In one embodiment, the stasis-inducing treatment comprises administering a therapeutically effective amount of a chalcogenide, salt, or prodrug thereof. The method of treating cancer may optionally comprise an additional step of withdrawing a portion of blood from said patient, such that blood flow to said cancer is further reduced or eliminated. In additional embodiments, the method of treating cancer may optionally comprise an additional step of diverting a portion of the blood flow in said patient, such that blood flow to said cancer is further reduced or eliminated.
Abstract: The invention relates to an implant for the human or animal body, which on its outer surface comprises at least one calcium salt that is soluble in a polar liquid. The invention also refers to various methods for the preparation of the preceding implant. The calcium ions contained on the surface of the implant provide said surface with four chemically and biologically advantageous properties: hydrophilicity, protection against atmospheric contamination, a pro-coagulant property and a pro-mineralising property.
Abstract: Nutritional compositions having dietary nucleotides, ?-3 fatty acids and citrulline are provided. The nutritional compositions may be formulated to improve T cell function, increase arginine availability in vivo, regulate myeloid-derived suppressor cells (“MDSC”), and decrease the risk and/or severity of infection after surgery or trauma. Methods of making, using and administering such nutritional compositions to individuals in need of same are also provided. Methods for modulating the affects of MDSC's are also provided.
Abstract: The present invention provides methods and compositions for treating thyroid-related medical conditions. Many thyroid-related medical conditions exist that go undiagnosed and untreated. These conditions may be prevented and treated with reduced folates and vitamin B12. Administration of reduced folates and vitamin B12 will prevent or treat cerebrospinal folate deficiency, which is linked to thyroid-related medical conditions. Administration of reduced folates and vitamin B12 will also prevent or treat conditions associated with masked megaloblastic anemia and hypothyroidism, and other conditions brought upon through improper thyroid function. Additionally, it is commonplace to treat many thyroid conditions with anti-thyroid drugs or thyroid stimulating drugs. This practice alone is also responsible for causing, or not beneficially addressing, adverse conditions that can be prevented or treated through the methods and compositions discussed herein.
Abstract: A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound. A magnesium-counter ion composition described herein may be useful for any of a variety of applications provided herein, such as maintaining, enhancing, and/or improving health, nutrition, and/or another condition of a subject, and/or cognitive, learning, and/or memory function. A magnesium-counter ion composition provided herein may be useful for administration to a subject presenting magnesium deficiency, mild cognitive impairment, Alzheimer's disease, attention deficit hyperactivity disorder, ALS, Parkinson's disease, diabetes, migraine, anxiety disorder, mood disorder, and/or hypertension. A kit, method, and other associated technology are also provided.
Abstract: The present invention is a composition and methods of administering the composition to improve a person's mental and physical health by increasing energy levels, motivation, willingness to communicate, appetite, and memory. The composition may be used to treat mental conditions by improving a person's wiliness and ability to communicate. The increase in appetite effect of the composition may be used to treat eating disorders. The composition comprises a carbohydrate, one or more NAD+/NADP+ producing vitamins, poly-sulfurous chelating agents, vasodilating salts, coenzyme-A producing vitamins, antioxidants, kinins, and biological energy sources.
Abstract: Compositions containing calcium phosphate and microcrystalline cellulose are useful as excipients in the preparation of solid dosage forms containing active pharmaceutical ingredients, particularly those prepared by processes involving multiple compaction steps. The recompactibility performance of such compositions is improved through the use of calcium phosphate having a relatively small particle size, e.g., a median particle size of not more than about 20 microns or not more than about 10 microns.
Type:
Grant
Filed:
November 2, 2010
Date of Patent:
January 21, 2014
Assignee:
FMC Corporation
Inventors:
Gregory Thoorens, Bruno LeClercq, Thomas Ruszkay
Abstract: A method for treating muscle cramping (e.g., acute nocturnal) includes the steps of placing a transdermal delivery agent on skin above an affected muscle that is in spasm. The transdermal delivery agent includes a composition that includes a therapeutic amount of magnesium. Placement of the transdermal delivery agent on the skin results in transdermal delivery of the magnesium directly to the affected muscle that is in spasm, thereby providing therapeutic relief while limiting the delivery of the magnesium to the entire circulatory system (systemic effect).
Abstract: The present invention relates to a galenic composition suitable for administration to a non-human animal, including at least the following three components: one or more active principles; an agent for accelerating delitescence; an agent for delaying delitescence, wherein the agent for accelerating delitescence an the agent for delaying delitescence are integrated in the composition so as to form a matrix with the controlled release of the active principle(s). The invention also relates to the uses of said compositions, as well as to a method for measuring the in vitro delitescence thereof.
Abstract: The subject matter of the present invention is in particular the use of an amino acid sequence of IDE, or of an analogue or fragment thereof, or of at least one nucleic acid sequence encoding this sequence, as a biomarker, or as an active agent, with regard to a dandruff condition of the scalp.
Type:
Application
Filed:
December 12, 2011
Publication date:
December 19, 2013
Applicant:
L'oreal
Inventors:
Caroline Delattre, Philemon Sirven, Dominique Bernard
Abstract: The invention is directed to a composition for the use to increase joint stability or postural stability, wherein said composition comprises branched chain amino acids. It is further directed to the use of branched chain amino acids for the preparation of a food supplement or medicament for the prophylaxis and/or treatment of joint and/or postural instability.
Abstract: Technologies are described herein for styptic compounds comprising a hemostatic or styptic agent suspended within a hydrophobic carrier medium. Example carrier mediums may include waxes, lipids, oils, or combinations thereof. The compound may be a semisolid at room temperature and soft enough to be easily dispensed and formed into or onto bleeding tissue of an animal or human. The hydrophobic qualities of the carrier medium can protect the styptic agent from absorbing moisture. The carrier medium can mechanically support positioning treatments adjacent to the bleeding tissue. The carrier medium can further serve to mechanically seal the tissue to aid in hemostasis while also protecting the tissue from debris and contamination. The carrier medium can aid in maintaining moisture within the tissue. Slurry-based manufacturing processes can support a substantially homogeneous dispersal of styptic agent throughout the carrier medium.
Abstract: There is provided an external-use composition that is incorporated with a hydrogen storing metal alloy keeping the hydrogen and generating the hydrogen, and that has the antioxidant effect, anti-inflammation effect and antiallergic effect. There is provided a skin external-use composition that is incorporated with a fine particle of hydrogen storing alloyed metal, such as magnesium hydride.
Type:
Application
Filed:
February 17, 2012
Publication date:
December 5, 2013
Applicants:
HYDROGEN HEALTH MEDICAL LABO CO., LTD., BIO COKE LAB. CO. LTD.
Abstract: The present invention provides compositions comprising silicon and at least one other joint health ingredient such as glucosamine, chondroitin, hyaluronic acid, collage, etc. as well as methods for making and using the same.
Abstract: The present invention provides a cell eradication method and a cell eradication principle for necrotizing a cell by agitating a cell using a physical turning force from the impression of an AC magnetic field, after preparing a magnetic nanowire having a dipole and introducing the magnetic nanowire into a cell. Therefore, the composition for inducing cell eradication of the present invention, when applied to a cell that is requested to be removed such as a cancer cell, can eradicate the cell by applying a physical impact through the rotation of the nanowire introduced inside the cell. Additionally, the heat generated from induced current from the magnetic field impression can add an effect of thermotherapy, and also, attaching a drug to the surface of the nanowire enhances the treatment effects.
Type:
Application
Filed:
January 31, 2012
Publication date:
November 21, 2013
Applicant:
KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION
Inventors:
Sung Hoi Choi, Jung Rae Park, Young Keun Kim
Abstract: A method of treating hearing loss includes the step administering a composition to the mammal, wherein the composition consists essentially of a biologically effective amount of vitamin A, vitamin E, vitamin C, a vasodilator comprising magnesium, and, optionally, a withanolide, and/or resveratrol.
Type:
Application
Filed:
March 15, 2013
Publication date:
November 14, 2013
Inventor:
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Abstract: Methods and compositions are disclosed to treat neuropsychiatric disorders based upon a new framework of diagnosis. Axis I biomarkers include genes related to prefrontal dopamine synthesis and/or dopamine degradation. Axis II includes genes related to re uptake of dopamine, norepinephrine and serotonin and autonomic hyperactivity. Axis III includes genes relates to impairments in inflammatory pathways, glutamate neurotransmission and/or neurotrophic factors. Axis IV includes genes related to glutamate reuptake and predisposition to addictive behavior, and obsessive compulsions.
Abstract: Methods for facilitating joint immobilization or fusion using selective estrogen receptor modulator (SERM) such as raloxifene are disclosed. The SERM may be administered systemically or locally. In conjunction with SERM, other therapeutic agents such as calcium, vitamin D, bone morphogenetic protein may be administered simultaneously. The method can similarly be applied to facilitate bone repair, bone healing, and connective tissue healing processes in a patient.
Abstract: The invention features a galvanic particulate including a first conductive material and a second conductive material, wherein both the first conductive material and the second conductive material are exposed on the surface of the particulate, wherein the particle size of the particulate is from about 10 nanometers to about 100 micrometers, wherein the second conductive material comprises from about 0.01 percent to about 10 percent, by weight, of the total weight of the particulate, and wherein the difference of the standard potentials of the first conductive material and the second conductive material is at least about 0.2 V.
Type:
Application
Filed:
April 25, 2013
Publication date:
November 7, 2013
Applicant:
Johnson & Johnson Consumer Companies, Inc.
Inventor:
Johnson & Johnson Consumer Companies, Inc.
Abstract: Implantable medical devices having galvanic particulates are disclosed. The particulate may be coated onto at least part of a surface of the medical device. In addition, the galvanic particulates may be contained in the material used to manufacture the antimicrobial medical devices, or may be embedded into the surface of the medical devices. The present invention also provides novel coating methods and processing methods. The present invention further provides a combination of galvanic particulates with an aqueous gel, a method of making this combination, and a method of treatment using this combination. The devices and compositions may have advantageous characteristics and effects including anti-microbial, anti-inflammatory, tissue regeneration promoting, and pain reduction or elimination.
Type:
Application
Filed:
July 9, 2013
Publication date:
November 7, 2013
Inventors:
Jennifer Hagyoung Kang Choi, Chunlin Yang, Ying Sun, Carrie H. Fang, James E. Hauschild, Abla A. Creasey
Abstract: A composition and method for treating a bone condition of an animal. The composition includes a nanoformulation of active ingredients. The active ingredients include Lepidium Sativum or other Lepidium extracts, calcium, vitamin D, and antioxidants. The method for treating a bone condition includes introducing the composition into the animal.
Type:
Grant
Filed:
October 27, 2010
Date of Patent:
October 22, 2013
Inventors:
Shaker A. Mousa, Mohammed H. Qari, Mohammed S. Ardawi